President Michel Cosnard

Antti Sajantila

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

Unit name:

From population diversity to a unique individual, from identification to identity

MANAGEMENT TEAM

The unit will be headed by Mr Bertrand Ludes from the Institute of Legal Medicine (IML) Université Paris Descartes, with a deputy head Ms Anne-Marie Bacon from the Centre National de la Recherche Scientifique (CNRS).

HCERES NOMENCLATURE

SVE5; SVE6.

SCIENTIFIC DOMAIN

The research topics of the BABEL project aim to take a fresh look at human identification, with a brave step beyond mainstream identity testing, based on standardized DNA-analysis, fingerprints and odontology. This is achieved by providing biological profile for the identity of an individual using modern extended DNAgeno-and phenotyping methods combined with epigenetic analysis for age estimation and ethnogeographical origins of the individual. The topics are applied in a large set of real-world forensic samples, which may vary from minute samples to highly destructed human corpses or part of them. In addition, a new approach is taken to analyse various trauma types, and contact material associated with them using modern imaging technology (micro-CT) and histology.

The core topics of the BABEL project can be grouped in classical disciplines as: forensic genetics, forensic pathology, forensic anthropology, human evolution, molecular anthropology and population genetics. In addition to the biomedical and natural sciences, the BABEL unit aims to borrow experts, methods and concepts also from humanities; sociology and psychology.

UNIT WORKFORCE

GLOBAL ASSESSMENT OF THE UNIT

For the first time in Europe, such a multidisciplinary unit would be created to focus on the common theme of identification, and identity at large, in the complex context of legal medicine.

Each of the merging groups has a productive scientific background of their own. The unit members are dedicated to academic education.

With the success of the BABEL unit the Institute of Legal Medicine should establish itself as one of the leading institutes in its field in Europe, and -at the same time -a global example of the potential of multidisciplinary science around legal medicine with a difficult task to serve the rapidly changing society. Thus, there is an immediate impact of the results from BABEL project, which can be translated to practice and potential for commercial products.

To conclude, the scientists in the BABEL unit have an excellent international reputation and have very good chances to develop an attractive training program for PhD students and post-doctoral scientists. They also have immediate impact outside of academic world, e.g. with the application of the science to societal needs of police and judicial system.

The evaluation reports of Hceres are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions Evaluation of research Evaluation of doctoral schools Evaluation of programmes International evaluation and accreditation

  LOCATION OF THE UNIT The BABEL is a new unit composed of researchers from the Institute of Legal Medicine (IML) in the Université Paris Descartes, gathering researchers from the IML, CNRS UMR 5288 AMIS (Molecular Anthropology and Synthesis Imaging, Toulouse), the former CNRS UPR 2147 (Dynamics of Human Evolution, Paris), and INTS (National Institute of Blood Transfusion, Paris). The proposed BABEL unit will be under the supervision of the University of Paris Descartes and CNRS, in association with the INTS and the Prefecture of Police in Paris.

  time research associates (Chargés de recherche) and similar positions 1 1Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc."


President Michel Cosnard

Chairman Adriaan Ijzerman

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

INTRODUCTION HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The future laboratory results from the merging of two well-established laboratories from University René Descartes: the "Laboratoire de Cristallographie et RMN Biologiques" (LCRB) and the "Chimie Organique, Médicinale et Extractive et Toxicologie Expérimentale" unit (COMETE) both associated with the CNRS, INSB and INC, respectively. These laboratories are located on the premises of the Faculty of Pharmacy, "rue de l'Observatoire", in part in renovated areas but mostly in premises that would require renovation.

MANAGEMENT TEAM

The unit will be directed by Mr Nicolas LEULLIOT (Paris Descartes), with Ms Isabelle BROUTIN and Mr Philippe BELMONT as deputy directors.

HCERES NOMENCLATURE

SVE2-1; ST4-1; ST4-3; ST4-4.

SCIENTIFIC DOMAIN

The old laboratories and the new unit have expertise in, and will focus on, integral aspects of the drug discovery process, including chemistry (natural products, synthetic and medicinal chemistry, analytical chemistry including metabolomics), computational approaches (molecular modelling), biology (biochemistry, structural biology), pharmacology (mechanisms of (inter)action, pharmacokinetics), drug delivery (biopharmaceutics, formulation), and toxicology.

UNIT WORKFORCE

GLOBAL ASSESSMENT OF THE UNIT

The proposed unit aims to become a high-performing research department covering most of the drug discovery pipeline. The integration process may be the first step in a further restructuring of the Paris Descartes Faculty of Pharmacy's research into two more research departments. If successful, it will surely improve the visibility of the research performed in this section of the School of Pharmacy and may help in attracting young talent from elsewhere as well as additional funding, from both public and private partners. The seven teams involved in the project are complementary, constitute a good mix of fundamental and applied science, and are well positioned to develop strongly supportive technology platforms and core facilities for researchers inand outside of the unit. On the average, they all have a very good scientific production, with some items of excellence. All PIs have national visibility and a few of them are internationally known. They are able to collect money from national agencies and charities and their training of students is very good. Our discussions with the PIs of the new research department were informative and inspiring, providing credit to a true desire of turning the new unit into a success. At this early stage there are no joint research outcomes yet; therefore, the committee can only conclude that the department's ambition and objectives are well defined and provide a clear path forward for the 2019-2023 term. In view of the anticipated development of additional core facilities, the infrastructure of the new unit needs further attention.

The evaluation reports of Hceres are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions Evaluation of research Evaluation of doctoral schools Evaluation of programmes International evaluation and accreditation

HCERES scientific officer: Mr Georges MASSIOT Representatives of supervising institutions and bodies:

	Unit name:	Cibles Thérapeutiques et Conception de Médicaments
	Unit acronym:	CiTCoM
	Requested label:	UMR + ERL
	Application type:	Restructuration
	Current numbers:	UMR 8015 and UMR 8638
	Head of the units (2017-2018):	Mr Nicolas LEULLIOT and Mr Olivier LAPREVOTE
	Project leader (2019-2023):	Mr Nicolas LEULLIOT
	Number of teams:	7
	COMMITTEE MEMBERS
	Chair:	Mr Adriaan IJZERMAN, Leiden University, Netherlands
	Experts:	Ms Martine CADENE, CNRS, Orléans
		Mr Karl GADEMANN, University of Zurich, Switzerland
		Mr Hervé KOVACIC, Université d'Aix-Marseille (representative of CNU)
		Mr Sylvain LACLEF, Université de Picardie (supporting personnel)
		Mr Roland MARQUET, Université de Strasbourg (representative of CoNRS)
		Ms Christa MUELLER, Universität Bonn, Germany
		Ms Eva PEBAY-PEYROULA, Université Grenoble Alpes
		Ms Natacha ROCHEL, Université de Strasbourg
		Mr Didier ROGNAN, Université de Strasbourg (representative of CoNRS)
		Mr Jean Louis BEAUDEUX, Université Paris Descartes
		Mr Erick DUFOURC, CNRS
		Ms Karine GIOVANNANGELI, Inserm

Ms Christine GUILLARD, Inserm Mr Hughes LORTAT JACOB, CNRS Mr Stephano MARULLO, Université Paris Descartes Mr Marius RÉGLIER, CNRS Cibles Thérapeutiques et Conception de Médicaments, U Paris 5, CNRS, Mr Nicolas LEULLIOT and Mr Olivier LAPREVOTE


President Michel Cosnard

Keith Muir

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

SCIENTIFIC DOMAIN

The unit is focused on basic, translational and clinical neuroscience.

UNIT WORKFORCE

GLOBAL ASSESSMENT OF THE UNIT

The unit is in the process of implementing a new scientific strategy involving organisational and physical reconfiguration. This new strategy will strengthen the unit's excellent potential for translational research, especially in the fields that are clinical strengths of the unit, principally cerebrovascular diseases and psychiatry. The unit has recruited basic and translational research teams of international standing across several fields of research, and the research strategy includes recruitment of junior research teams. The unit additionally includes a number of core facilities to support the range of basic and translational neuroscience activities. There are a number of common research interests across the teams that are already prompting new collaborations and joint grant applications. Research outputs of the unit are very good to excellent, and funding from major national funders supports most teams. The unit provides very good training for PhD students in translational and clinical research. The unit provides a framework for collaborative research, and where appropriate, has very good levels of public and societal engagement and interactions with the wider scientific community. The unit has very good engagement with industry and promotes commercialisation activities, including filing of patents.

The evaluation reports of Hceres are available online: www.hceres.com

Evaluation of clusters of higher education and research institutions Evaluation of higher education and research institutions Evaluation of research Evaluation of doctoral schools Evaluation of programmes International evaluation and accreditation

INTRODUCTION

  HISTORY AND GEOGRAPHICAL LOCATION OF THE UNITThe IPNP is located in a new building at the Hôpital St Anne site. The IPNP is a new configuration arising as a result of re-organisation of several historical research teams based at the hospital and/or in the Centre for Neuroscience de Paris. Since 2016, the IPNP has been formed by assembling new research teams on the advice of an International Scientific Advisory Board in conjunction with the director and in consideration of the optimal potential for translational neuroscience. The research unit was reorganised under the current director from late 2015 in order to manage a transition to a new grouping of research teams and to oversee the move into a new building that opened in February 2017. The unit continues the site's experience in clinical psychiatry and neurology research, but has expanded by adding a number of teams. Many of the teams have joined or relocated to the new building within the months preceding the visit.

Representatives of supervising institutions and bodies:

Ms